5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com - Jefferies has reduced its price target on Virbac SA (EPA:VIRB) to EUR333.00 from EUR346.00 while maintaining a Hold rating on the stock.
The adjustment follows Virbac’s first-half results, with Jefferies refreshing its estimates and lowering 2025-2029 revenue projections by 2% to 4% and adjusted EBITA by approximately 5%.
Jefferies noted that while Virbac is expected to have a stronger second half, these gains would be offset by near-term headwinds from adverse foreign exchange rates.
The research firm highlighted that Virbac’s new CEO Paul Martingell has endorsed the company’s 2030 adjusted EBITA margin target of 20%, viewing it as essential for demonstrating sustainable growth.
According to Jefferies, Martingell sees mergers and acquisitions as a partial driver for achieving this growth target at the animal health company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.